These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32571298)

  • 21. The continual reassessment method for dose-finding studies: a tutorial.
    Garrett-Mayer E
    Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-finding designs for cumulative toxicities using multiple constraints.
    Lee SM; Ursino M; Cheung YK; Zohar S
    Biostatistics; 2019 Jan; 20(1):17-29. PubMed ID: 29140414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TITE-BOIN-ET: Time-to-event Bayesian optimal interval design to accelerate dose-finding based on both efficacy and toxicity outcomes.
    Takeda K; Morita S; Taguri M
    Pharm Stat; 2020 May; 19(3):335-349. PubMed ID: 31829517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monitoring late-onset toxicities in phase I trials using predicted risks.
    Bekele BN; Ji Y; Shen Y; Thall PF
    Biostatistics; 2008 Jul; 9(3):442-57. PubMed ID: 18084008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges in implementing model-based phase I designs in a grant-funded clinical trials unit.
    Frangou E; Holmes J; Love S; McGregor N; Hawkins M
    Trials; 2017 Dec; 18(1):620. PubMed ID: 29282111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determining a maximum tolerated cumulative dose: dose reassignment within the TITE-CRM.
    Braun TM; Levine JE; Ferrara JL
    Control Clin Trials; 2003 Dec; 24(6):669-81. PubMed ID: 14662273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE.
    Walker K; Hinsley S; Phillip R; Oughton JB; Murden G; Chalmers AJ; Faivre-Finn C; Greystoke A; Brown SR;
    JCO Precis Oncol; 2022 Nov; 6():e2200133. PubMed ID: 36446040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.
    Yuan Y; Lin R; Li D; Nie L; Warren KE
    Clin Cancer Res; 2018 Oct; 24(20):4921-4930. PubMed ID: 29769209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. U-PRO-CRM: designing patient-centred dose-finding trials with patient-reported outcomes.
    Alger E; Lee SM; Cheung YK; Yap C
    ESMO Open; 2024 Jul; 9(7):103626. PubMed ID: 38968929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surv-CRM-12: A Bayesian phase I/II survival CRM for right-censored toxicity endpoints with competing disease progression.
    Andrillon A; Chevret S; Lee SM; Biard L
    Stat Med; 2022 Dec; 41(29):5753-5766. PubMed ID: 36259523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I dose-escalation oncology trials with sequential multiple schedules.
    Günhan BK; Weber S; Seroutou A; Friede T
    BMC Med Res Methodol; 2021 Apr; 21(1):69. PubMed ID: 33853539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.
    Tevaarwerk A; Wilding G; Eickhoff J; Chappell R; Sidor C; Arnott J; Bailey H; Schelman W; Liu G
    Invest New Drugs; 2012 Jun; 30(3):1039-45. PubMed ID: 21225315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A regression based phase I clinical trial for late-onset toxicities without clinician elicitation.
    Chapple AG; Wojcik JJ; McDaniel LS
    Contemp Clin Trials Commun; 2019 Jun; 14():100327. PubMed ID: 30766934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection of the initial design for the two-stage continual reassessment method.
    Jia X; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):495-506. PubMed ID: 28300466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRM and partial order CRM with adaptive rescaling for dose-finding in immunotherapy trials with a continuous outcome.
    Saha PT; Fine JP; Ivanova A
    Stat Med; 2023 Jun; 42(14):2409-2419. PubMed ID: 37012897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial.
    Huang B; Kuan PF
    Biom J; 2014 Nov; 56(6):933-46. PubMed ID: 24895140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
    O'Connell NS; Wages NA; Garrett-Mayer E
    Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.